Hyderabad  - A high-level delegation from the U.S. Food and Drug Administration (FDA) visited the Telugu states on February 23-25. Led by Mark Abdoo, the FDA’s Associate Commissioner for Global Policy and Strategy, the delegation appeared February 25th at Hyderabad’s BioAsia 2023 Summit, where he participated in a panel discussion entitled “India for India and India for the World: Where Does Quality Stand?” FDA drug product experts separately traveled to Andhra University on February 23-24 for a workshop with pharmaceutical industry leaders, scholars, and regulatory officials.

“Telangana is one of the states with the most FDA-registered drug manufacturing facilities and Andhra University plays a key role in India’s pharmaceutical ecosystem,” said Associated Commissioner Abdoo. “Industry and regulators need to work together to achieve safe and effective medical products for global consumption. I believe the conversations I’ve had over the last few days has helped identify important ways we can facilitate that cooperation.”

In the United States, the FDA is charged with protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. As Associate Commissioner for Global Policy and Strategy, Mr. Abdoo is responsible for providing executive oversight, strategic leadership and policy direction to FDA’s global policy, operations, trade, and diplomacy activities. He was joined by Sarah McMullen, Ph.D., director of the FDA’s India Office; and Carmelo Rosa, PsyD., director of the Division of International Drug Quality in the FDA’s Center for Drug Evaluation and Research.